We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Test Identifies Mortality Risk for Trauma Patients

By LabMedica International staff writers
Posted on 04 Feb 2013
A simple, inexpensive blood test performed on trauma patients upon admission can help doctors easily identify patients at greatest risk of death. More...


A computerized tool that combines factors like age, gender, and common blood tests known as the complete blood count (CBC) and the basic metabolic profile (BMP) can determine an individual's mortality risk is now available to physicians.

Scientists at the Intermountain Medical Center (Salt Lake City, UT, USA) studied 9,538 patients and discovered that some trauma patients are far more likely to die than others were, regardless of the severity of their original injuries. The Intermountain Risk Score is a computerized tool and has been helpful in evaluating individuals with medical problems like heart failure or chronic pulmonary disease. The benefit of the tool had not been tested for trauma patients hospitalized due to an accident or traumatic injury, rather than an underlying condition.

The Intermountain Medical Center used the tool to categorize patients according to high, moderate, and low risk levels. Some surprising findings emerged as high-risk men were nearly 58 times more likely to die within a year than low-risk men were. Men with a moderate risk were nearly 13 times more likely to die than those with low risk. High-risk women were 19 times more likely to die within a year than low-risk women were, and women with moderate risk were five times more likely to die than those with low risk.

Sarah Majercik, MD, an Intermountain Medical Center surgeon, said, "As surgeons, we don't often use all of the CBC results in evaluating a patient who needs surgery for a bleeding spleen or after a motor vehicle accident. There are certain values, such as hemoglobin, hematocrit, and platelets that we scrutinize closely as part of good clinical care, but then other parts, such as the red blood cell distribution width (RDW) that we pay no attention to at all in the acute setting. These factors are generally overlooked, even though they are part of the CBC that every trauma patient gets when he or she arrives in the emergency room." The study was presented on January 18, 2013, at the 27th annual Scientific Session of the Eastern Association for the Surgery of Trauma held in Phoenix (AZ, USA).

Related Links:
Intermountain Medical Center


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Lead author Professor Chamindie Punyadeera. (Image Credit: Griffith University)

Breath Analysis Shows Promise for Distinguishing Cancerous from Benign Lung Nodules

Lung nodules are frequently detected during imaging, but distinguishing malignant from benign findings can require invasive procedures. Some patients undergo biopsies, bronchoscopy, or surgery before learning... Read more

Molecular Diagnostics

view channel
Image: Skin samples from people with a suspected genetic myopathy were examined for confirmation of disease. Brown spots show abnormal protein buildup inside the nuclei of cells (purple), typical of a type of myopathy called oculopharyngodistal myopathy. (Image Credit: Garvan Institute)

Long-Read Sequencing Test Identifies Genetic Causes in Inherited Muscle Disease

Inherited muscle diseases are highly heterogeneous and often progressive, leaving many patients without a molecular diagnosis despite extensive testing. Conventional assays typically target individual... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.